Relative efficacy and safety of loratadine, hydroxyzine, and placebo in chronic idiopathic urticaria.

Paper

Relative efficacy and safety of loratadine, hydroxyzine, and placebo in chronic idiopathic urticaria.

Published Sep 1, 1992 · Eugene W. Monroe, David I. Bernstein, Roger W. Fox

Arzneimittel-Forschung

UNKNOWN SJR score

52

Citations

0

Influential Citations

Semantic Scholar

Abstract

The efficacy and safety of a new non-sedating antihistamine, loratadine (Clarityn, CAS 79794-75-5) 10 mg q.d., was compared to the classical antihistamine, hydroxyzine 25 mg t.i.d. and placebo in a 4-week (optional 12 week) randomized, double-blind, multi-center study in 203 patients with chronic idiopathic urticaria. Efficacy evaluations included weekly physician and patient assessments of pruritus, overall disease condition, and therapeutic response to treatment. Loratadine and hydroxyzine were significantly more effective than placebo and clinically comparable to each other as measured by all efficacy evaluations at each visit. Loratadine was safe and well tolerated with sedation and dry mouth similar to placebo and significantly less than hydroxyzine.

RCT

Study Snapshot

Loratadine and hydroxyzine are both effective and safe treatments for chronic idiopathic urticaria, with loratadine showing less sedation and dry mouth than hydroxyzine.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Paper

Relative efficacy and safety of loratadine, hydroxyzine, and placebo in chronic idiopathic urticaria.

References

Citations

Evaluation and Management of Angioedema in the Emergency Department

Emergency physicians should focus on airway management and evaluate the patient's history, medications, and family history to effectively treat angioedema.

Chronic Urticaria: Comparisons of US, European, and Asian Guidelines

The 2017 revision and update to chronic urticaria guidelines reconciles differences between US, European, and Asian guidelines, improving diagnosis and management of the condition.

Current and future therapies for the treatment of histamine-induced angioedema

There are no formal guidelines for treating histamine-induced angioedema, and understanding its mechanism is crucial for determining the appropriate treatment algorithm.

Guideline of Chronic Urticaria Beyond

Omalizumab effectively controls chronic urticaria in 2/3 of cases, but its mechanism of action and duration of treatment remain unclear.

H1-antihistamines for chronic spontaneous urticaria: an abridged Cochrane Systematic Review.

H1-antihistamines at standard doses effectively and safely suppress chronic spontaneous urticaria, with no evidence to suggest differences in adverse event rates.